CD47 and neoplasm: Many studies have confirmed that blocking CD47 interaction with SIRPα can enhance cancer cell clearance via macrophage inhibition of CD47/SIRPα interaction, which may increase antigen cross-presentation, leading to an adaptive anti-tumor immune response with T-cell priming [52].